Q2 Solutions Q2 Solutions Actionable Insights for Better Health and Lab Solutions
Insight Brief
Radha Krishnan, MD | August 01, 2017

Fighting Cancer: Biomarkers for Immuno-Oncology Clinical Trials

Using anatomic pathology for biomarker development in clinical trials can help predict and assess how a patient will respond to immuno-oncology therapies
At Q2 Solutions, we're attacking cancer from many angles, but one approach we're particularly excited about is the use of anatomic pathology for biomarker development in clinical trials. This technology can help predict and assess how a patient will respond to immuno-oncology (IO) therapies, which are some of the most promising new treatments clinicians have to fight cancer.

In this insight brief, learn how anatomic pathology can become an integral part of successful cancer research outcomes for customers and patients, as well as 3 key challenges to biomarker development in clinical trials.

Author:
Kadha Krishnan, MD, Chief Pathologist and Senior Medical Director

Related Services:
Advancing Precision Medicine through Anatomic Pathology

Tissue-based Molecular Testing and Companion Diagnostics

Anatomic Pathology brochure

Comprehensive in-house end-to-end anatomic pathology and adjunct molecular services

Read More